Home > Boards > US OTC > Delisted >

Biopure Inc. (fka BPURQ)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/14/2011 9:32:41 AM - Followers: 4 - Board type: Free - Posts Today: 0



 

Outstanding Shares:  39,709,015 Shares.

Authorized Shares:  200,000,000 Shares.

Number Of Shareholders:  870.

 

Company Status:  In CH11 process, no liquidation value.

 

Important Websites

Home Page: http://www.biopure.com/
Investor Kit: http://www.biopure.com/corporate/reports/bpur_ekit.zip

Corporate Contact

Biopure Corporation
11 Hurley Street
Cambridge, MA 02141
Phone 617-234-6500
Fax 617-234-6505

About Biopure Corporation (Nasdaq: BPUR)

Biopure Corporation develops, manufactures and markets oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. Using our patented and proprietary technology, we have developed and manufacture two products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)] for human use, and Oxyglobin® (HBOC-301) [hemoglobin glutamer - 200 (bovine)] for veterinary use. Hemopure is being sold in South Africa for the treatment of adult surgical patients who are acutely anemic and for eliminating, reducing or delaying the need for allogenic red blood cell transfusion in these patients. A marketing authorization application for Hemopure is pending in the United Kingdom, also for a surgery indication.

We have been developing Hemopure for the treatment of patients with cardiovascular ischemia and supporting the U.S. Navy's government-funded development of the product for out-of-hospital treatment of trauma patients in hemorrhagic shock. To exploit the body of preclinical and clinical information we have involving anemia, we are now beginning development for use of Hemopure in anemic cancer patients and end-of-life patients.

Oxyglobin, our veterinary product for the treatment of anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration (FDA) and the European Commission. We have sold approximately 200,000 units of Oxyglobin.

We are headquartered and operate a cGMP manufacturing facility in Cambridge, Massachusetts.

Products

Oxygen Bridge
The purpose of intravenous oxygen-delivery support is to help stabilize the patient and prevent tissue damage or organ dysfunction associated with oxygen deprivation. When Hemopure or Oxyglobin is infused into the bloodstream, its chemically stabilized hemoglobin molecules both carry oxygen in the plasma (the fluid part of blood) and facilitate the release of oxygen from red blood cells, thereby increasing diffusion of oxygen to tissues. If necessary, this effect can be extended over time by repeat dosing to provide a continuous Oxygen Bridge until anemic or ischemic patients receive other appropriate therapy.

Hemopure South Africa
HBOC-201 [hemoglobin glutamer - 250 (bovine)]
Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)], is a first-in-class product for human use and approved in South Africa for the treatment of acutely anemic adult surgical patients. Its purpose is to eliminate, reduce or delay these patients' need for allogenic red blood cell transfusions.

Current list: http://www.biopure.com/technology_and_products.php

Biopure Corporation Management


Zafiris G. Zafirelis
Chairman, President and Chief Executive Officer
Zafiris G. Zafirelis has been President, Chief Executive Officer and a director of Biopure since June 2004. In January 2006 he was appointed Chairman of the Board. Before coming to Biopure, he was CEO and a director of MedQuest Product, Inc, Salt Lake City, UT, a pioneering developer of implantable ventricular assist devices. He previously served as CEO and a director of CardiacAssist, Inc., Pittsburgh, PA, and, for four years prior to Biopure's initial public offering, as Director of Product Applications at Biopure. He holds a graduate diploma in chemistry from the University of Rhodesia and an M.B.A. from the University of Southern California.


David A. Butler
Interim Chief Financial Officer
Mr. Butler most recently served as Vice President, Finance and Administration at the Millard Group, Inc., a services & consulting company. Prior to that position, he served as Vice President, Finance, Chief Financial Officer and Treasurer at Circe Biomedical, Inc., a development-stage medical device manufacturer, formerly in Lexington, Mass.


Jane Kober
Senior Vice President, General Counsel and Secretary
Jane Kober has been Senior Vice President, General Counsel and Secretary of Biopure since 1998. From June 1989 to April 1998, she was a partner in LeBoeuf, Lamb, Greene & MacRae, L.L.P. Ms. Kober holds a J.D. degree from Case Western Reserve University, an M.A. degree from the University of Chicago and a B.A. in English from the Pennsylvania State University. She serves as a director of HTV Industries, Inc.


Geoffrey J. Filbey
Vice President, Engineering
Geoffrey J. Filbey joined Biopure in 1985 and has served as Vice President, Engineering since 1995. He previously worked at Stone & Webster Engineering Corporation for 14 years as a project manager and process engineer. Prior to Stone & Webster, he was a plant manager for eight years at Morganite Carbon Co. in London. Mr. Filbey holds a B.Sc. degree in engineering from the City University in London, England.


A. Gerson Greenburg
Vice President, Medical Affairs
A. Gerson Greenburg, M.D., Ph.D. joined Biopure as Vice President, Medical Affairs, in May 2006. He is a board-certified general surgeon and expert in oxygen therapeutics with over 40 years of experience in clinical care, quality systems, teaching and research. A professor emeritus of surgery at Brown University School of Medicine in Providence, R.I., Dr. Greenburg retired from The Miriam Hospital in April 2006 after serving as chief of clinical quality management since 2003 and as surgeon-in-chief from 1986 to 2005. In 2005, he received the hospital's Charles C.J. Carpenter Outstanding Physician of the Year Award. Previously, he was chief of general surgery and surgical intensive care at the Veterans Administration Medical Center in San Diego, Calif., and was a professor of surgery at the University of California, San Diego.


W. Richard Light
Vice President, Technology Development
W. Richard Light, Ph.D., rejoined Biopure as Vice President, Technology Development, in February 2005. During the previous year, Dr. Light was Vice President, Development, at Aeris Therapeutics in Woburn, Mass. He originally joined Biopure in 1990 and has held several positions, including Vice President, Process Technology; Director, Product Development; and Associate Director, Analytical and Protein Chemistry. Dr. Light previously served as a research biochemist and postdoctoral fellow at the Naval Research Laboratory in Washington, D.C. He holds a Ph.D. in biochemistry from Rice University, and has a B.S. in biology and a B.A. in chemistry from Washington & Lee University.


Virginia T. Rentko
Vice President, Preclinical Development
Virginia T. Rentko, V.M.D. is Vice President, Preclinical Development, at Biopure. She is board certified in internal medicine and is an adjunct clinical assistant professor in the Department of Clinical Sciences at Tufts University School of Veterinary Medicine. Dr. Rentko received her V.M.D. degree from the University of Pennsylvania and completed clinical training at the University of Pennsylvania and Tufts University. She obtained her M.S. degree in Zoology at the Ohio State University and her B.S. degree in Biology at Boston University. She is a diplomate of the American College of Veterinary Internal Medicine, and is an active member of the Association of Veterinary Hematology and Transfusion Medicine and the American Veterinary Medical Association.


Barry L. Scott
Vice President, Business Development
Barry L. Scott has been Vice President, Business Development, since September 2003. He joined the company in June 2002 as Vice President, International Business Development. From 1998 until 2002 Mr. Scott worked for Bristol-Myers Squibb Company, most recently as Vice President, International Business Development, Europe. From 1996 until 1998 he was the general manager of Bristol-Myers Squibb, Ltd., South Africa. He also held several positions, including Director of Marketing and Sales, during his 20 years at Merck Sharp and Dhome, the South Africa subsidiary of Merck & Co. Mr. Scott holds the Diploma in Education from the University of Rhodesia and the Diploma in Marketing Management from the Institute of Marketing Management, South Africa.

Filings and Other Information

http://sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000815508&owner=include&count=40

News

http://investor.biopure.com/phoenix.zhtml?c=114417&p=irol-news&nyo=0

Chart and Stock Information

Share Structure

O/S: 33,918,000

Ref: http://investor.biopure.com/phoenix.zhtml?c=114417&p=IROL-secToc&TOC=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvY29udGVudHMueG1sP2lwYWdlPTU1MzkzMjYmcmVwbz10ZW5r

American Stock Transfer & Trust Co.
Shareholder Services
59 Maiden Lane, Plaza Level
New York, NY 10038
Phone: 800-937-5449
Fax: 718-236-2641

Charts



_______________________________________
Updated 16 MAY 2008 by Soapy Bubbles

PostSubject
#347   BPURQ: SEC Suspension and ADMIN Proceeding: Renee 07/14/11 09:32:40 AM
#346   hmmmm.... MrMiyagi3000 06/23/11 02:24:55 AM
#345   ME to i had lots of bpurq at Rtrite 06/10/10 11:45:46 PM
#344   Who dumped 300,000 shares at 0.006? Why? Will Value_Investor 01/13/10 12:25:58 PM
#343   It is because someone bought over 6M cheap Value_Investor 01/08/10 11:47:51 AM
#342   WHY IS THIS pos MOVING ? taraniterror 01/07/10 01:44:39 PM
#341   It is up 125%! Please do not sell Value_Investor 01/07/10 11:20:06 AM
#340   This CH11 stock has 0.0041 ~ 0.005 per Value_Investor 01/05/10 11:35:09 AM
#339   "Buy Confirmed" by AmericanBull! Let's push the price Value_Investor 12/29/09 12:47:06 PM
#338   Who are those very stupid sellers who sold Value_Investor 12/28/09 03:23:00 PM
#337   Sell....Buy....Sell...Buy.......Would laugh at this one but I made trent777 12/28/09 04:36:44 AM
#336   High Probability of Reversal - BPURQ ILuvGreen3 12/25/09 06:56:04 PM
#335   i thought you said to sell it!! hahahaa!! Icanslim 12/24/09 11:57:32 PM
#334   BPURQ is finally bottomed out at 0.0041 today! Value_Investor 12/24/09 04:08:10 PM
#333   New 52-week low .0041 was created today! Sell Value_Investor 12/23/09 12:51:13 PM
#332   New 52-week low .0051 was created today! Sell Value_Investor 12/22/09 12:58:35 PM
#331   New 52-week low 0.0071 was created today! Sell Value_Investor 12/21/09 04:09:31 PM
#330   Who are those very stupid sellers which sold Value_Investor 12/18/09 03:07:06 PM
#329   It is strong up 57% today from 0.008 Value_Investor 12/17/09 03:18:07 PM
#328   New 52-week low 0.008 was created today! Sell Value_Investor 12/16/09 10:45:01 AM
#327   "Sell Confirmed" by AmericanBull! I bet another new Value_Investor 12/11/09 10:13:08 AM
#326   Why the other people could sell the shares Value_Investor 12/09/09 12:03:11 PM
#325   I am glad to see BPURQ was up Value_Investor 12/07/09 04:58:05 PM
#324   It is finally bottomed out at 0.011! I Value_Investor 12/04/09 11:03:32 AM
#323   New 52-week low 0.011 was created yesterday! Sell Value_Investor 12/02/09 11:04:11 AM
#322   You're welcome, hubstocker. jhnvtjll 11/10/09 02:53:25 AM
#321   jhnvtjll thanks. hubstocker 11/07/09 09:44:24 AM
#320   I've never had warrants either. Personally, I wouldn't jhnvtjll 11/07/09 02:49:13 AM
#319   Never had warrants before and tried reading up hubstocker 11/06/09 10:17:17 PM
#318   BPURQ is Class A common stock and BPUFQ jhnvtjll 11/06/09 08:09:02 PM
#317   What is the difference between BPURQ and BPUFQ ticker? hubstocker 11/06/09 07:15:16 PM
#316   I guess no value here huh ? Man, taraniterror 11/05/09 10:54:05 AM
#315   New 52-week low .015 was created today! Sell Value_Investor 11/05/09 10:23:28 AM
#314   New 52-week low 0.019 was created today! It Value_Investor 11/04/09 11:25:41 AM
#313   New 52-week low 0.02 was created today! 0.02 Value_Investor 11/02/09 02:32:18 PM
#312   Another new 52-week low 0.021 was created today! Value_Investor 10/30/09 03:05:20 PM
#311   New 52-week low 0.022 was created yesterday! Smart Value_Investor 10/29/09 12:18:45 PM
#310   Smart sellers dumped near 100,000 shares at 0.025 Value_Investor 10/28/09 09:54:43 AM
#309   Who are those very smart sellers which dumped Value_Investor 10/21/09 12:18:24 PM
#308   Who are those very smart sellers which sold Value_Investor 10/16/09 09:17:13 AM
#307   Who are those very smart sellers which sold Value_Investor 10/15/09 09:23:13 AM
#306   Who are those very stupid sellers which sold Value_Investor 10/09/09 09:56:01 AM
#305   Who are those very stupid sellers who sold Value_Investor 10/07/09 11:57:20 AM
#304   Former Executive of Massachusetts Public Company Sentenced to scion 10/06/09 07:11:20 PM
#303   http://sec.gov/litigation/litreleases/2009/lr21238.htm nosecret 10/06/09 04:45:19 PM
#302   Who are those very stupid sellers who had Value_Investor 10/06/09 12:26:54 PM
#301   I am glad to own over 1M damn Value_Investor 09/30/09 12:38:44 PM
#300   The pos scam seems bottomed out at 0.025 Value_Investor 09/24/09 02:26:10 PM
#299   "Sell" confirmed by AmericanBull. We should see the Value_Investor 09/18/09 09:21:32 AM
#298   As I predicted the pos scam is heading Value_Investor 09/16/09 02:30:56 PM
PostSubject